

## References

### I-9130

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Soliris prescribing information. Alexion. June 2019.
3. Ultomiris prescribing information. Alexion. June 2021.
4. National Institute of Neurological Disorders and Stroke. Myasthenia Gravis Fact Sheet. NIH Publication No. 17-768. July 2018.
5. Legendre, C.M., et al. “Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome — NEJM.” *New England Journal of Medicine*, Alexion Pharmaceuticals., 6 June 2013. 368 (23): 2169-81.
6. Fakhouri, F., et al. “Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.” *American Journal of Kidney Diseases*. 2014;63(1):40-48.
7. Myasthenia Gravis Foundation of America. Myasthenia Gravis: A Manual for the Health Care Provider (PDF). 2010.
8. National Organization for Rare Disorders (NORD). NORD Rare Disease Database. Atypical Hemolytic Uremic Syndrome.
9. National organization for Rare disorders (NORD). Rare Disease Database. Neuromyelitis Optica Spectrum Disorder.
10. Bu F, Maga T, Meyer N, et al. Comprehensive Genetic Analysis of Complement and Coagulation Genes in Atypical Hemolytic Uremic Syndrome. *J Am Soc Nephrol*. 2014 Jan; 25(1):55-64.
11. Geerdink LM, Westra D, van Wijk JA, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. *Pediatr Nephrol*. 2012 Aug; 27(8): 1283-1291.
12. Goodship THJ, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO Controversies Conference. *Kidney International*, Volume 91, Issue 3, 539 – 551.
13. Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis. Executive summary. *Neurology* 2016;87:419-425.
14. Sahin Fahri, Meltem Akay O, Ayer M, et al. Pesg PNH diagnosis, follow-up and treatment guidelines. *Am J Blood Res*. 2016; 6(2): 19-27.

15. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*. 2015 Jul 14; 85(2): 177-189.
16. Regulatory workshop on clinical trials designs in neuromyelitis optica spectrum disorders (NMOSD). 16 June 2015.
17. Rupesh R, Krishnappa V, Blaha T, et al. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. *Therapeutic Apheresis and Dialysis* 2019; 23(1):4-21.
18. Johnson S, Stojanovic J, Ariceta G, et al. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. *Pediatr Nephrol* 2014;29:1967-78.